

## **Blis Technologies Gets Key 'Letter of No Objection' From US Food and Drug Administration for Ingredient BLIS K12**

28 January 2016

Blis Technologies Limited announces that one of the company's key products, the ingredient BLIS K12, has had the issuance of a US Food and Drug Administration 'Letter of No Objection'.

The Letter of No Objection, more commonly known as GRAS or 'Generally Recognized As Safe', is another step on the strategic pathway to open markets through regulatory approval.

It adds a new level of credibility for BLIS K12 and has the potential to put the conversations with larger consumer food and beverage companies in the US on a stronger footing.

Many of those companies are, quite rightly, risk averse and therefore having GRAS status offers an additional level of confidence. GRAS status makes it clearer where BLIS K12 fits within the category.

Through the GRAS program, companies may submit their determination supported by research and expert review that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.

Peter Fennessy  
Chairman